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Background: Hepatitis C virus (HCV) imposes a considerable disease burden in China, with at least 10 million
people chronically infected. Little is known about the financial impact of the HCV epidemic, nor about the extent
to which various forms of insurance are providing HCV patients with financial protection. A cross-sectional multi-site study
was conducted to acquire data that will aid policy-makers and other stakeholders in developing effective strategies to
address this situation.
Methods: At 29 hospitals across China, inpatients and outpatients with chronic HCV were surveyed about their insurance
coverage and medical costs. Percentages, means and medians were calculated, and differences in continuous variables
among multiple groups were analyzed using the Kruskal-Wallis test or Wilcoxon two-sample test.
Results: Many inpatients (N = 593) and outpatients (N = 523) reported being covered by one of three major types of
government health insurance, but 13 % of inpatients and 43 % of outpatients reported having no insurance. Among
inpatients, the total median cost per hospitalization per patient was 8212 Renminbi (RMB). The category of expenditure
with the highest median cost per hospitalization was Western medicine, followed by lab tests and Chinese medicine.
The median cost per hospitalization was far higher for patients who had hepatocellular carcinoma than for those with
less severe forms of liver disease. Outpatient antiviral therapy costs ranged from a median of 377 RMB for ribavirin to a
median of 37,400 RMB for pegylated interferon-alpha for up to one year of treatment.
Conclusions: For uninsured chronic HCV patients in China, inpatient and outpatient costs may be financially
devastating. Research is needed on how different approaches to financing HCV treatment and care might
improve health outcomes as well as achieve cost savings by enabling more people to be cured of HCV.
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In China, chronic hepatitis C virus (HCV) infection is in-
creasingly recognized as a public health problem that has
major consequences for individuals, families and society
in general. At least 10 million people in mainland China
are chronically infected with HCV [1–3], and annual
HCV incidence has increased considerably in recent years
[4]. Chronic hepatitis C infection is one of the leading
causes of cirrhosis and hepatocellular carcinoma (HCC).
Usually, 10 to 15 % of HCV-infected patients are expected
to develop cirrhosis, and the risk of HCC in persons with
cirrhosis is approximately 2–4 % per year [5, 6]. Therefore
China is thought to have a considerable burden of HCV-
associated cirrhosis and HCC.
Hepatitis C is a curable disease [6, 7], and advances in
HCV therapy have resulted in steadily higher cure rates.
New direct-acting antivirals (DAAs) represent a major
breakthrough in the treatment of HCV infection, but these
drugs are not generally available in mainland China. Cur-
rently either interferon or peg-interferon (PEG-IFN) com-
bined with ribavirin (RBV) is still the first-line HCV
treatment in China [4, 5]. The use of PEG-IFN/RBV has
resulted in sustained viral response rates ranging from 44
to 83 % in a number of Chinese studies [4], representing
somewhat better outcomes than those observed worldwide
for PEG-IFN/RBV. While PEG-IFN/RBV is much cheaper
than the DAA regimens, the cost of PEG-IFN/RBV still
imposes a heavy financial burden on many HCV pa-
tients in China.
The Chinese health system incorporates multiple types
of insurance that offset medical costs for covered individ-
uals, although a lack of comprehensive national data makes
it difficult to determine the extent to which people are util-
izing different types of insurance to meet their health
needs. Major categories of insurance include the govern-
ment employee program; government public program for
urban areas; government public program for rural areas;
commercial health insurance; and government-provided
catastrophic health insurance. The government employee
program, which is provided by the national government, is
only for civil servants who are national or local govern-
ment employees. The government public program for
urban areas is provided by the national government for
urban residents, and the insured individual must submit an
annual co-pay. The government public program for rural
areas is offered to farmers by national and local govern-
ments, and farmers also have a co-pay. Commercial health
insurance, provided by private insurance companies, is
available to anyone who meets the specified requirements.
Catastrophic health insurance provided by the national
government is a kind of supplementary insurance for basic
national health insurance plans including the government
employee program, government public program for urban
areas, and government public program for rural areas. Ifthe patient suffers from a life-threatening or highly debili-
tating disease, or if medical expenses exceed the limitation
of the basic national health insurance coverage, the add-
itional amount will be paid through catastrophic medical
insurance. There are other types of insurance for popula-
tions such as military personnel and college students. Some
people do not purchase any government or private health
insurance, and thus are responsible for meeting all of their
health care costs.
The financial impact of the HCV epidemic in China is
not well known. This evidence gap threatens to under-
mine efforts to develop strategies that will improve out-
comes for HCV patients. In this study, we conducted
cross-sectional multisite surveys of outpatients and inpa-
tients with chronic HCV infection. Our purpose was to
acquire data that will guide policy-makers and other rele-
vant stakeholders in making decisions that will contribute
to reducing the burden of HCV disease in China.
Methods
Study population
China is a very large country with many different regions
and with different levels of development across regions.
In an effort to reflect the overall national situation, we
conducted a cross-sectional survey at 29 hospitals in 20
provinces in all regions of China (North, Northeast, East,
Middle, South and Northwest) (Fig. 1). Sixteen of the 29
participating hospitals were tertiary hospitals and 13
were secondary hospitals. The 29 hospitals included 11
infectious disease specialty hospitals.
Inpatients and outpatients with a diagnosis of chronic
hepatitis C were eligible to participate in the study if they
were at least 18 years old and if they had tested serum-
positive for anti-HCV Ab or HCV-RNA (confirmed by
either HCV-RNA quantitative real-time PCR test or quali-
tative test) at least six months before study enrollment.
Inpatients had undergone at least one hospital admission.
Outpatients were only eligible to participate in the study if
they had been seen for at least one year at the hospital
where study enrollment was taking place. Patients were
excluded from study participation if they had HIV, other
forms of viral hepatitis, cancer, cardiovascular disease or
other serious health conditions; if they had underlying
liver disease due to other factors such as autoimmune fac-
tors, alcohol consumption or drug use; or if they were
pregnant or breastfeeding. Hepatocellular carcinoma was
regarded differently since it was a condition of interest for
investigators, and having HCC did not disqualify patients
from study participation.
Data collection
To ensure consistency in how data were collected, the
principal investigators from all study sites underwent
training at Beijing Youan Hospital before study enrollment
Fig. 1 Geographic distribution of participating hospitals. Legend: Provinces with hospitals that participated in the study appear in blue
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and exclusion criterion, as well as introducing standard
procedures for how to communicate with patients and
how to instruct them to complete the study questionnaires.
Each site was asked to enroll 40 to 45 individuals, includ-
ing at least 20 inpatients and 20 outpatients. Sites stopped
enrolling new study participants when they reached this
target. Outpatients completed questionnaires in the waiting
room of the outpatient department. Inpatients completed
questionnaires in a quiet room in the inpatient department.
Physicians provided in-person instruction to patients re-
garding how to complete the questionnaires. Data collec-
tion took place from 1 May to 31 December 2011. During
this time, a designated clinical associate from Beijing
Youan Hospital was charged with responding immediately
to questions from the study sites.
Different questionnaires were used for outpatients and
inpatients. Both questionnaires included the same four sec-
tions. The first section asked for the patient’s name and for
demographic information such as age, sex and place of
residence. The second section addressed the patient’s gen-
eral condition, including the following information: the age
when he or she was diagnosed with hepatitis C; insurance
status; disease stage; disease complications; and time of
hospitalization. The third section asked about the patient’s
treatment history, including whether the patient received
antiviral therapy; the names of antiviral medications;
whether therapy to protect liver function was received; and
whether traditional Chinese medicines were utilized.The fourth section collected information about various
medical costs. Inpatients were asked about costs per
hospitalization, including the cost of Western medica-
tion, traditional Chinese medicine, laboratory tests, bed
charges and nursing. For HCC patients, additional
questions were asked about the costs of HCC-specific
treatment and HCC-related surgery. For outpatients,
antiviral treatment costs were requested.
The questionnaire was designed in the Chinese lan-
guage. All questions were expressed in short simple sen-
tences such as “Where do you come from?” and “How old
are you?”. Study investigators explained questions to pa-
tients who could not read. After each patient completed
his or her questionnaire, the answers were checked against
the patient’s medical records for accuracy. If differences
were identified, the information in the medical record was
used. Data management was performed by a professional
statistician to ensure the soundness of the data.
Study participants were categorized according to dis-
ease severity using the following criteria. People who
had chronic HCV but did not have a diagnosis of either
cirrhosis or HCC were designated as “chronic HCV, no
cirrhosis or HCC”. The diagnosis of chronic hepatitis C
was based on the criteria used by the Chinese Society of
Hepatology and the American Association for the Study
of Liver Diseases (AASLD) [5, 8]. People who had been
diagnosed with cirrhosis via liver biopsy or imaging but
did not have a diagnosis of HCC were “chronic HCV
plus cirrhosis”. People who had been diagnosed with
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cirrhosis, were “chronic HCV plus HCC”. The diagnosis
of HCC was based on AASLD guidance and utilized
radiology, AFP serology, and/or biopsy [9].
Data analysis
Statistical analysis was performed using IBM SPSS Statis-
tics for Windows, version 19.0 (IBM Corp, Armonk, NY,
USA). Data were expressed as the mean (standard devi-
ation), median or number (percentage). If the data had
non-normal distributions, differences in continuous vari-
ables among multiple groups were analyzed using the
Kruskal-Wallis Test or Wilcoxon Two-Sample Test be-
tween two groups. A two-sided p-value of <0.05 was con-
sidered statistically significant. For the comparison of
inpatient costs by type of insurance, four categories were
used: one for no insurance and the other three for the
three types of insurance that cover nearly 85 % of Chinese
citizens: government employee program, government urban
public program and government rural public program [10].
Research ethics
The study protocol was approved by the Institutional
Review Board of Beijing Youan Hospital, Capital Medical
University and the study was performed in accordance
with the provisions of the Declaration of Helsinki 1975Table 1 Sociodemographic characteristics of study participants
Tota
Gender (%) Female 529
Male 587
Age, mean (standard deviation) 47.5
Age, median (P25, P75) 48.0
Age, range (minimum, maximum) 68 (






Months elapsed since diagnosis, mean (standard deviation) 35.5
Months elapsed since diagnosis, median (P25, P75) 18.0
Months elapsed since diagnosis, range (minimum, maximum) 333





Northwest 151and its revision. Written informed consent was ob-
tained from all study participants. Personal information
collected by investigators was only used for study pur-
poses. Data were managed using identification numbers
that were assigned to protect the privacy of study
participants.
Results
Among 1149 questionnaires submitted, 1116 (97.1 %)
fulfilled data collection requirements (593 from inpa-
tients and 523 from outpatients). Fifty-three percent of
these 1116 respondents were male and 47 % were fe-
male. More than 90 % of respondents were aged 30 or
older. A higher number of outpatients than inpatients
were younger than 30 years, while more inpatients than
outpatients were older than 60 years. An average of
18 months had elapsed from the first confirmed diag-
nosis of HCV infection to the time of study enrollment
(Table 1).
Health insurance coverage
Compared with outpatients, more inpatients were cov-
ered by the government public programs for urban and
rural health (46.4 % versus 30.0 % and 25.6 % versus
12.4 %, respectively). Up to 43.0 % of all outpatients re-
ported paying for medical expenses on their own, whilel patients (n = 1116) Inpatients (n = 593) Outpatients (n = 523)
(47.4) 276 (46.5) 253 (48.4)
(52.6) 317 (53.5) 270 (51.6)
(13.1) 49.1 (12.8) 45.5 (13.3)
0 (39,57) 48.0 (40,58) 46.00 (37, 55)
18,86) 68 (18,86) 65 (18, 83)
(9.8) 39 (6.9) 70 (13.4)
(17.6) 97 (16.4) 99 (18.9)
(29.9) 178 (30.0) 156 (29.8)
(24.9) 153 (25.8) 125 (23.9)
(13.3) 96 (16.2) 52 (9.9)
4.5) 30 (5.1) 21 (4.0)
(47.9) 34.0 (47. 6) 37.4 (48.4)
(11.0, 38.0) 18.0 (8.0, 37.3) 22.0 (12.0,39.0)
.0 (0.0, 333.0) 325.0 (0.0, 325.0) 333.0 (0.0, 333.0)
(18.0) 109 (18.4) 92 (17.6)
8.6) 54 (9.1) 42 (8.0)
(27.2) 158 (26.6) 146 (27.9)
(25.4) 141 (23.8) 142 (27.1)
7.3) 40 (6.7) 41 (7.8)
(13.5) 91 (15.3) 60 (11.5)









Total 593 12,720 14,595 8212 5098 15,358
Western medicine 577 8255 11,192 4701 2539 9610
Lab tests 569 1574 1386 1302 709 1977
Chinese medicine 245 1038 2861 314 120 812
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own. (Table 2).
Inpatient cost per hospitalization and major categories of
expenditure
The total median cost for hospitalization per time per
patient was 8212 RMB. While Western medicine was
the category of expenditure with the highest median cost
(4701 RMB), mean costs for lab tests and Chinese medicine
both exceeded 1000 RMB (Table 3). Since traditional
Chinese medicine has been in existence for thousands of
years, it is worth noting that the mean cost of Chinese
medicine was about 8 % of the total cost of hospitalization.
Inpatient costs by type of insurance
We further analyzed inpatient medical costs per time per
person by comparing inpatients with insurance coverage
through the government employee program to those
covered through the government urban public program
and government rural public program, as well as those who
were uninsured. The median total cost per hospitalization
before insurance payout was 12,117 RMB for patients in
the government employee program, 9535 RMB for patients
in the government urban public program and 6340 RMB
for patients in the government rural public program.
Patients without insurance reported a median total cost per
hospitalization of 6937 RMB. The differences were statisti-
cally significant (X2 = 41.27, p < 0.0001) (Table 4).
Relationship between cost of hospitalization and level of
hospital
Two hundred and sixty-four inpatients (44.5 %) were
treated in secondary hospitals and 329 (55.5 %) were
treated in tertiary hospitals. The median total cost of
one hospitalization per time per patient in RMB was
significantly higher in tertiary hospitals than in second-





N (%) N (%)
Government employee program (total) 75 12.7 73 14.0
With catastrophic health insurance (2)
Government public program, urban (total) 275 46.4 157 30.0
With catastrophic health insurance (1) (5)
With commercial health insurance (1) (2)
Government public program, rural (total) 152 25.6 65 12.4
With commercial health insurance (2)
With catastrophic health insurance (1)
Other types of health insurance 12 2.0 3 0.6
Uninsured 79 13.3 225 43.0Hospitalization expenses in relation to disease stage
Inpatient costs were assessed by disease stage, with pa-
tients classified as “chronic HCV, no cirrhosis or HCC”,
“chronic HCV plus cirrhosis” or “chronic HCV plus
HCC”. The median total cost increased significantly with
the severity of the disease stage, from 8112 RMB to 8399
RMB to 14,425 RMB (p = 0.0353) (Table 6).
Outpatient expenses for antiviral therapy
Among the 404 outpatients who had received antiviral
therapy, the following median costs were reported for a
treatment duration of up to one year: 37,400 RMB for
pegylated interferon-alpha (N = 197), 6798 RMB for
interferon-alpha (N =185) and 377 RMB for ribavirin (N
= 341) (Table 7).
Discussion
To our knowledge, this is the first study to examine
medical costs associated with management of chronic
HCV infection in mainland China. Although fairly high
proportions of both inpatients and outpatients reported
being covered by one of China’s three major types of
government health insurance, 13 % of inpatients and
43 % of outpatients reported having no insurance.
Among inpatients, the total median cost per
hospitalization per patient was 8212 RMB. The category
of expenditure with the highest median cost per
hospitalization was Western medicine, followed by lab testsTable 4 Inpatient costs by type of insurance (in Renminbi)
N Median
cost
P25 P75 X2 P value*
Government employee
program
67a 12,117 7531 17,989 41.27 <0.0001
Government urban
public program
274b 9535 5623 16,667
Government rural public
program
152 6340 4262 9056
Uninsured population 83c 6937 5061 18,273
*The Kruskal-Wallis test was used for comparisons
a8 responses were excluded from analysis because the information was
incomplete or implausible
b1 response was excluded from analysis because the information was
incomplete or implausible
c25 responses were excluded from analysis because the information was
incomplete or implausible
Table 5 Hospitalization expenses and level of hospital (in Renminbi)
N Mean cost Standard deviation Median cost P25 P75 Z* P value*
Secondary Hospitals 264 10,268 11,181 6780 4016 12,196 −5.7639 <0.0001
Tertiary Hospitals 329 14,687 16,599 9778 6075 17,633
*The Wilcoxon Two-Sample Test was used for comparisons
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was much higher for patients who had hepatocellular car-
cinoma than for those with less severe forms of liver dis-
ease. Additionally, outpatients reported high costs for
antiviral drugs.
Beginning in the late 1990s, the Chinese government
implemented a series of reforms for the purpose of mak-
ing health care more affordable, but it is not clear whether
the intended benifits are being realized [11, 12]. Our study
of chronic HCV patients found that even while study par-
ticipants reported utilizing all three major types of govern-
ment health insurance, a high proportion of patients had
no insurance of any kind. The impact of this situation on
individual and household financial well-being may be dev-
astating in light of the high costs associated with HCV
disease.
The median cost per hospitalization for uninsured inpa-
tients in our study was reported to be almost 7000 RMB.
Although this study did not disaggregate outpatient anti-
viral therapy costs by insurance status, the fact that more
than two in five outpatients were uninsured suggests that
a considerable number of people paid out-of-pocket for
pegylated interferon-alpha, interferon alpha and ribavirin.
The median costs reported for these medicines were
37,400 RMB, 6798 RMB and 377 RMB respectively. To
put these inpatient and outpatient costs in context, China
had an annual per-capita income of 23,979 RMB in cities
and towns in 2011, while the annual per-capita income for
rural residents was 6977 RMB [13]. Thus it would be un-
surprising for a single hospitalization to consume one-
third of an uninsured urban HCV patient’s annual income
or the entirety of an uninsured rural HCV patient’s annual
income. The costs of the PEG-IFN/RBV and IFN/RBV
regimens for outpatients are also far out of proportion to
what the average Chinese person earns.
Insurance coverage gaps for HCV patients may also
have grave implications for patient outcomes. In our
study, the median inpatient cost per hospitalization for
uninsured patients was 6937 RMB – slightly more thanTable 6 Inpatient costs by disease stage (in Renminbi)
N Median P25 P75 X2 P*
Chronic HCV, no
cirrhosis or HCC
485 8112 5144 15,344 6.685 0.0353
Chronic HCV plus
cirrhosis
95 8399 4746 15,004.0
Chronic HCV plus HCC 13 14,425 14,114 25,995
*The Kruskal-Wallis test was used for comparisonsthe median for patients covered by the government rural
public insurance program. In contrast, median costs per
hospitalization were more than 9500 RMB and more
than 12,000 RMB for inpatients covered by the govern-
ment employee insurance program and government
urban public insurance program respectively. While this
difference might be attributable to multiple reasons, one
troubling possibility is that uninsured inpatients are re-
ceiving less of the health care services that they need be-
cause of perceived or actual inability to pay. The finding
thus points to an important issue that warrants further
attention from Chinese researchers and policy-makers.
Research elsewhere has directly assessed the health con-
sequences of a lack of insurance for HCV patients. A re-
cent study by Younossi et al. reported that during the
years 2005 to 2009, uninsured HCV patients in the
United States had a 49 to 72 % greater chance of dying
during a hospitalization than HCV patients who had in-
surance [14] .
Our analysis of the cost of hospitalization in relation to
HCV disease stage indicated that a hospitalization for an
HCV patient with hepatocellular carcinoma was typically
far more costly than a hospitalization for an HCV patient
who did not have HCC. Research from Canada and the
United States also has found higher costs to be associated
with more advanced HCV disease stage. A Canadian study
that utilized modeling data for the estimated national
population of HCV-infected people projected increasingly
higher lifetime HCV costs for patients at more advanced
disease stages [15]. In a large US cohort, chronic HCV pa-
tients with end-stage liver disease had far higher all-cause
health care costs than chronic HCV patients with noncir-
rhotic liver disease or those with compensated cirrhosis.
Approximately half of costs were HCV-related, with a
higher proportion of HCV-related costs concentrated
among patients with end-stage liver disease [16].
While this relationship between cost and disease stage






197 37,968 22,182 37,400 17,550 59,424
Interferon-alpha 185 7256 6397 6798 2790 9877
Ribavirin 341 643 1055 377 172 660
aThe amount attributed to each antiviral drug was for up to one year
of treatment
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treatment to chronic HCV patients in China may be well
less than the cost of managing patients with untreated
chronic HCV, and research is urgently needed to explore
cost-benefit dynamics in the Chinese context. A US study
quantified the direct economic burden of HCV infection
and PEG-IFN/RBV treatment for HCV from 2002 to 2007,
and found that PEG/IFN-RBV-treated patients had higher
total direct medical costs than untreated HCV patients (US
$28,547 vs. US $21,752; P < 0.001) [17]. Other research has
found that despite the high cost of antiviral treatment, com-
pared to discontinued therapy patients, chronic hepatitis C
patients who completed interferon therapy and presumably
had a higher rate of achieving sustained viral response were
found to have lower levels of healthcare resource utilization
and costs post-therapy [18]. Also, Federico et al. [19]
showed that Canadian patients who had cleared the virus
had the lowest time and out-of-pocket costs. Thus it seems
feasible that increasing the use of antiviral therapy for HCV
in China can reduce the overall economic burden in
addition to improving health outcomes, and it is important
for policy-makers to explore the potential for expansions in
insurance coverage to contribute to overall financial gains
in this regard.
This study has some limitations. First it is a cross-
sectional investigation which does not reflect the dynamic
changes in medical costs for all HCV patients. Second, the
sample size is not large enough. A larger investigation
needs to be conducted to acquire a more comprehensive
dataset that can reliably guide health policy decision-
making. Finally, there might be some recall bias in this
study, such as the exact time of HCV diagnosis. Since we
investigated outpatient medical cost within one year and
per hospitalization cost, we consider it played a minor im-
pact on the analysis of medical costs.
Conclusions
For uninsured chronic HCV patients in China, inpatient
and outpatient costs may be financially devastating. Chinese
policy-makers need a better knowledge base in order to de-
velop informed strategies for expanding insurance coverage.
Research is needed on how different approaches to finan-
cing HCV treatment and care might improve health out-
comes as well as achieve cost savings by enabling more
people to be cured of HCV.
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